The ten-eleven translocation 2 gene (TET2) encodes a member of the TET family of DNA methylcytosine oxidases that converts 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC) to initiate the demethylation of DNA within genomic CpG islands. Somatic loss-of-function mutations of TET2 are frequently observed in human myelodysplastic syndrome (MDS), which is a clonal malignancy characterized by dysplastic changes of developing blood cell progenitors, leading to ineffective hematopoiesis. We used genome-editing technology to disrupt the zebrafish Tet2 catalytic domain. T ET2 belongs to the TET (ten-eleven translocation) family of methylcytosine oxidases, which require 2-oxoglutarate, oxygen, and Fe(II) for their activity. TET2, like TET1 and TET3, modifies the methylation status of the genome, regulating the transcription of specific genes by converting 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC) and then to 5-formylcytosine (5fC) and finally to 5-carboxylcytosine (5caC). Each of the last 3 products is recognized and excised by thymine DNA glycosylase (TDG), completing the removal of the 5-methyl group and regenerating unmodified cytosine (1). Hydroxylation of 5mC by the TET enzymes, returning cytosine to its unmethylated state, has been shown to be crucial to many aspects of embryonic development, including embryonic stem cell (ESC) renewal, epigenetic programming of zygotic cells, and meiosis of primordial germ cells (PGCs) (reviewed in references 2 and 3).A variety of alterations, including deletions and missense, nonsense, and frameshift mutations, inactivate the TET2 enzyme in different types of human myeloid malignancies, such as myelodysplastic syndromes (MDS) (25 to 35%) (4-7), myeloproliferative neoplasms (MPN) (2 to 20%) (8, 9), de novo acute myeloid leukemia (AML) (12 to 17%) (10-14), secondary AML (24 to 32%) (11,12), and chronic myelomonocytic leukemia (CMML) (50 to 60%) (5). In these diseases, TET2 gene alterations lead to a marked reduction in global levels of 5hmC (15). TET2 mutations have also been identified in the hematopoietic cells of otherwise healthy adults over 50 years of age who have "clonal skewing" of their bone marrow cells (16), indicating that TET2 mutations may represent one of the first mutations leading to clonal expansion and the eventual development of myeloid malignancies.The role of TET2 mutations in myeloid malignancies has been studied in a number of mouse models (17-20). The hematopoietic stem cells (HSCs) in these models have low 5hmC content and exhibit increased self-renewal ability and a competitive advantage over wild-type HSCs for repopulating hematopoietic lineages. Tet2 knockout mice are viable and fertile and appear to develop normally. However, as they age, Tet2-deficient mice are prone to develop myeloid malignancies, predominantly CMML, with 20 to 30% developing disease after 8 months of age, clearly suggesting that additional genetic lesions are needed to initiate myeloid malignancy.Thus, the essential role of TET2 in maintaining the normal growt...